11 recruiting, 6 completed, 4 not yet recruiting, 3 unknown. 14 Phase 2, 6 Phase 1, 4 Not applicable, 3 Phase 3.
Follow Locally Advanced Non-Small Cell Lung Cancer: new trials by email Literature Review of Locally Advanced Non-Small Cell Lung Cancer trials Research Report on Locally Advanced Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DS-3939a in Participants With Solid Tumors DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 400 | 2026-10-13 | 2026-10-28 |
| An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer Benmelstobart Combined With Anlotinib - Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer | Not applicable | Not yet recruiting | Zhejiang Cancer Hospital | 30 | 2026-10-01 | 2026-09-30 |
| Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity | Phase 2 | Recruiting | Indiana University | 10 | 2026-09-01 | 2026-09-15 |
| Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer Cromolyn Sodium - Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma | Phase 1 | Not yet recruiting | Carcinex Inc | 10 | 2026-08-01 | 2026-07-01 |
| Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC PD-L1/VEGF Bispecific Antibody, PD-1 Monoclonal Antibody, Nab-paclitaxel - Locally Advanced Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 290 | 2026-05-01 | 2026-10-07 |
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Sintilimab, Paclitaxel, Carboplatin (AUC 5) - Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Recruiting | Yang Hong | 28 | 2025-12-31 | 2026-04-30 |
| Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy - EGFR, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Peng Zhang | 160 | 2025-11-25 | 2026-08-03 |
| Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC Hypofractionated Radiation Therapy, Conventionally Fractionated Radiation Therapy, Concurrent Chemotherapy - Locally Advanced Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Sun Yat-sen University | 311 | 2025-07-01 | 2025-07-23 |
| Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC PM8002, Sintilimab, Nab-paclitaxel - Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 160 | 2025-02-18 | 2025-02-20 |
| RAPART in Locally Advanced Non-small Cell Lung Cancer Patients Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）, Conventional radiotherapy - Locally Advanced Non-small Cell Lung Cancer | Not applicable | Recruiting | Capital Medical University | 911 | 2025-02-17 | 2025-12-02 |
| Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Neoadjuvant therapy, Hypo-RT and concurrent chemotherapy, CFRT and concurrent chemotherapy - Neoadjuvant Therapy, Concurrent Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 497 | 2024-11-30 | 2025-07-24 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer concurrent or sequential chemoradiotherapy, Immunotherapy - Locally Advanced Non-small Cell Lung Cancer | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 200 | 2024-03-01 | 2024-03-01 | |
| Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT Anlotinib - Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy | Phase 2 | Completed | JIANYANG WANG | 44 | 2024-01-01 | 2026-10-07 |
| Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy Upfront resection - Locally Advanced Non-Small Cell Lung Cancer, Chemoradiotherapy | Not applicable | Unknown | The Netherlands Cancer Institute | 20 | 2023-04-01 | 2023-03-20 |
| Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy - Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Chest Hospital | 108 | 2022-10-09 | 2026-07-23 |
| Patient's Whole Process Follow-up Management(HOPE-1) Patients' whole process follow-up and management platform - Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC | Recruiting | Qianfoshan Hospital | 1268 | 2022-05-22 | 2022-09-08 | |
| Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Anlotinib, Chemotherapy, Radiotherapy - Locally Advanced Non-small Cell Lung Cancer, Efficacy and Safety | Phase 2 | Withdrawn | Sun Yat-sen University | 2022-04-01 | 2022-11-21 | |
| A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy Camrelizumab, PD-1 monoclonal antibody, Apatinib, VEGFR2 antibody - Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 42 | 2021-03-17 | 2022-08-16 |
| Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy - Locally Advanced Non-Small Cell Lung Cancer | Phase 1 | Completed | University of Oxford | 21 | 2020-12-07 | 2026-01-29 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1) · Cardiotoxicity (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Radiation Injuries (1)
Lung Diseases (15) · Neoplasms (15) · Neoplasms by Site (15) · Respiratory Tract Diseases (15) · Respiratory Tract Neoplasms (15) · Thoracic Neoplasms (15) · Bronchial Neoplasms (13) · Carcinoma, Bronchogenic (13) · Lung Neoplasms (13) · Adenocarcinoma (1) · Carcinoma (1) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Heart Diseases (1)
Carboplatin (7) · Chemoradiotherapy (3) · Cisplatin (3) · Paclitaxel (3) · Pemetrexed (3) · anlotinib (3) · 130-nm albumin-bound paclitaxel (2) · Immunotherapy (2) · Radiotherapy (2) · Surgical Procedures, Operative (2) · pembrolizumab (2) · sintilimab (2) · Albumin-Bound Paclitaxel (1) · Atovaquone (1) · Bevacizumab (1)
Sun Yat-sen University (3) · Peng Zhang (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Capital Medical University (1) · Carcinex Inc (1) · Centre Antoine Lacassagne (1) · Chinese Academy of Medical Sciences (1) · Daiichi Sankyo (1) · Fox Chase Cancer Center (1) · Indiana University (1) · JIANYANG WANG (1) · Kobe Minimally Invasive Cancer Center (1) · Lisette Nixon (1) · Loma Linda University (1)
China (16) · United States (5) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1) · Taiwan (1) · Tunisia (1) · Turkey (Türkiye) (1)
Hui Liu, Professor (3) · Peng Zhang, PhD (2) · Akito Hata (1) · Charles Owen (1) · David A. Bush, MD (1) · Gareth Griffiths, BSc, MSc, Cstat (1) · Geoffrey Higgins (1) · J. Timmer-Bonte, MD, Phd (1) · Jason Lester, MBBS, MRCP, FRCR (1) · Jerry D. Slater, MD (1) · Jordan Holmes, MD (1) · Koen Hartemink, MD, PhD (1) · Nan Bi, MD (1) · Ranee Mehra, MD (1)
PMID 11698646, PMID 15030777, PMID 15240681, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16227604, PMID 18565862, PMID 19426218, PMID 19515503, PMID 20516428, PMID 20530281, PMID 20625120, PMID 20636820, PMID 22867890, PMID 23775348, PMID 24422706, PMID 25601342, PMID 27718847, PMID 27745820, PMID 28271869, PMID 28397821, PMID 28885881, PMID 29454091, PMID 29556198, PMID 29570421, PMID 29658848, PMID 29658856, PMID 30206369, PMID 30207593, PMID 30280635, PMID 30285770, PMID 31331945, PMID 32366856, PMID 32577817, PMID 33294918, PMID 33438349, PMID 33476803, PMID 34377028, PMID 41082893